Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.
作者信息
Riethmüller Gert
机构信息
Institute for Immunology, Ludwig-Maximilians-Universität, München, Germany.
出版信息
Cancer Immun. 2012;12:12. Epub 2012 May 1.
Abstract
摘要
相似文献
1
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.
Cancer Immun. 2012;12:12. Epub 2012 May 1.
2
Targeting T cells to tumor cells using bispecific antibodies.
Curr Opin Chem Biol. 2013 Jun;17(3):385-92. doi: 10.1016/j.cbpa.2013.03.029. Epub 2013 Apr 25.
3
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Mol Immunol. 2006 Mar;43(8):1129-43. doi: 10.1016/j.molimm.2005.07.034. Epub 2005 Sep 1.
4
Characterization of a Novel Bispecific Antibody That Activates T Cells and Slows Tumor Growth .
Monoclon Antib Immunodiagn Immunother. 2019 Dec;38(6):242-254. doi: 10.1089/mab.2019.0035.
5
Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
J Mol Biol. 2012 Jul 13;420(3):204-19. doi: 10.1016/j.jmb.2012.04.020. Epub 2012 Apr 25.
6
Alternative molecular formats and therapeutic applications for bispecific antibodies.
Mol Immunol. 2015 Oct;67(2 Pt A):95-106. doi: 10.1016/j.molimm.2015.01.003. Epub 2015 Jan 27.
7
Bispecific antibodies and diabodies for cancer immunotherapy.
Immunotherapy. 2012 May;4(5):459-60. doi: 10.2217/imt.12.18.
8
Bispecific Antibody Armed T Cells to Target Cancer Cells.
Methods Mol Biol. 2018;1722:117-126. doi: 10.1007/978-1-4939-7553-2_8.
9
Bispecific antibodies for cancer therapy: A review.
Pharmacol Ther. 2018 May;185:122-134. doi: 10.1016/j.pharmthera.2017.12.002. Epub 2017 Dec 18.
10
Bispecific antibodies for polyclonal T-cell engagement.
Curr Opin Mol Ther. 2003 Aug;5(4):413-9.
引用本文的文献
1
Bispecific FpFs: a versatile tool for preclinical antibody development.
RSC Chem Biol. 2024 Sep 27;5(11):1147-64. doi: 10.1039/d4cb00130c.
2
Developability considerations for bispecific and multispecific antibodies.
MAbs. 2024 Jan-Dec;16(1):2394229. doi: 10.1080/19420862.2024.2394229. Epub 2024 Aug 27.
3
Facile Access to Branched Multispecific Proteins.
Bioconjug Chem. 2024 Jul 17;35(7):954-962. doi: 10.1021/acs.bioconjchem.4c00162. Epub 2024 Jun 16.
4
Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future.
Front Pharmacol. 2024 May 30;15:1399802. doi: 10.3389/fphar.2024.1399802. eCollection 2024.
5
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Signal Transduct Target Ther. 2024 May 22;9(1):126. doi: 10.1038/s41392-024-01826-z.
6
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer.
Cancers (Basel). 2023 Feb 23;15(5):1412. doi: 10.3390/cancers15051412.
7
Evolving Treatment Landscape of -mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond.
Cancers (Basel). 2023 Feb 17;15(4):1286. doi: 10.3390/cancers15041286.
8
Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors.
Pharmaceutics. 2022 Nov 11;14(11):2442. doi: 10.3390/pharmaceutics14112442.
9
Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours.
Nat Commun. 2022 Sep 7;13(1):5265. doi: 10.1038/s41467-022-32952-3.
10
The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials.
J Clin Pharm Ther. 2022 Sep;47(9):1337-1351. doi: 10.1111/jcpt.13741. Epub 2022 Jul 29.
本文引用的文献
1
Use of anti-receptor antibodies to focus T-cell activity.
Immunol Today. 1986 Jul-Aug;7(7-8):241-5. doi: 10.1016/0167-5699(86)90112-X.
2
IgG4-related disease.
N Engl J Med. 2012 Feb 9;366(6):539-51. doi: 10.1056/NEJMra1104650.
3
Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.
Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21182-7. doi: 10.1073/pnas.1118450109. Epub 2011 Dec 12.
4
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92. doi: 10.1073/pnas.1019002108. Epub 2011 Jun 20.
5
Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells.
Nat Immunol. 2011 Jun 19;12(8):770-7. doi: 10.1038/ni.2050.
6
Mechanism of immunoglobulin G4 Fab-arm exchange.
J Am Chem Soc. 2011 Jul 6;133(26):10302-11. doi: 10.1021/ja203638y. Epub 2011 Jun 15.
7
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.
8
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Clin Cancer Res. 2011 Jun 15;17(12):4101-9. doi: 10.1158/1078-0432.CCR-11-0407. Epub 2011 May 10.
9
Antibody-based therapeutics to watch in 2011.
MAbs. 2011 Jan-Feb;3(1):76-99. doi: 10.4161/mabs.3.1.13895. Epub 2011 Jan 1.
10
Metrics for antibody therapeutics development.
MAbs. 2010 Nov-Dec;2(6):695-700. doi: 10.4161/mabs.2.6.13603. Epub 2010 Nov 1.
Zotero 插件